The genetic architecture of postoperative delirium after major surgery and its relationship with non-postoperative neurocognitive conditions

Richard A. Armstrong,[1*] Paul Yousefi,[1,2] Ben Gibbison,[3] Golam M Khandaker,[1,2,4,5] Tom R Gaunt[1,2]

1 MRC Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol, UK.

2 NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and University of Bristol, Bristol, UK.

3 Bristol Medical School, University of Bristol, Bristol, UK.

4 Avon and Wiltshire Mental Health Partnership NHS Trust, Bristol, UK.

5 Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

***Correspondence to:** Richard A Armstrong

Email: ra17848@bristol.ac.uk

X: @drrichstrong

Short title: Genetic architecture of postoperative delirium

Abstract

Background

Postoperative delirium is the most common postoperative complication in older individuals. Genome-wide association studies (GWAS) can provide insights into how genetic factors influence postoperative risk. We examined the genetic architecture of postoperative delirium after major surgery and its relationship with related cognitive conditions (delirium of any type and Alzheimer's disease, including the *APOE* ε4 allele).

Methods and Findings

A GWAS was performed in UK Biobank to identify genetic variants associated with postoperative delirium. These results were then used in genetic correlation and polygenic risk score analyses to investigate shared genetic risk between postoperative delirium and a) delirium of all causes, and b) Alzheimer's disease.

The GWAS (1016 cases, 139,148 controls) identified six Single Nucleotide Polymorphisms (SNPs) that mapped to four genes (*APOE, TOMM40, APOC1* and *PVRL2*); $p < 5 \times 10^{-8}$. Five SNPs remained significant after excluding pre-existing dementia, and two after excluding subsequent dementia. The lead SNP was rs429358, a missense variant of *APOE*. Genetic correlation and polygenic risk score analyses revealed evidence of shared genetic architecture and risk between postoperative delirium and Alzheimer's disease (rho = 0.68, p<0.001). The *APOE* ε4 isoform had a dose-response effect on risk (OR [95% CI] for one and two copies 1.75 [1.53 – 2.0] and 4.19 [3.25 – 5.41] respectively, p <0.001).

Conclusions

We identified genetic variants associated with increased risk of postoperative delirium. We also found evidence of shared genetic liability with Alzheimer's disease suggesting that individuals with genetic risk of Alzheimer's disease, even without symptoms, may be at higher risk of postoperative delirium.

Introduction

Postoperative delirium is the most common postoperative complication in older individuals, with an incidence of up to 65% (1,2). It has substantial health and resource implications including increased morbidity, mortality and healthcare costs (1,3). Hypotheses of the underlying mechanisms span a range of pathways including release of excitotoxic neurotransmitters, neuronal injury and inflammation, physiological stressors, metabolic derangements, electrolyte disorders and genetic factors (1,2,4–8). Postoperative delirium has been associated with an increased risk of cognitive decline and incident dementia (9) but there is conflicting evidence on how the acute occurrence of postoperative delirium interacts with longer-term cognitive decline and neurodegeneration (10).

Whilst the aging global population and increasing numbers of older adults undergoing surgery have made perioperative brain health an increasing focus of research and clinical initiatives (11), the ability of clinical teams to produce personalised assessments of clinical risk for individuals remains limited. Improved detection of underlying biological risk in conjunction with established clinical risk factors could aid in preoperative risk prediction, facilitate better-informed shared-decision making and allow targeting of multicomponent interventions to prevent delirium (11) with potential reductions in morbidity, mortality and resource utilisation.

Population-based genome-wide association studies (GWAS) are a powerful approach for identifying genetic risk factors associated with complex conditions of multifactorial aetiology. Their results can aid prediction but also identify underlying

biological mechanisms and potential targets for intervention. They have been extensively applied to a wide range of clinical phenotypes (12), but rarely to postoperative delirium specifically. Previous GWAS that have included postoperative neurocognitive complications have failed to identify any genome-wide significant associations (13–15) - most likely because they suffered from limited sample sizes and heterogeneity of outcomes.

This study aimed to evaluate the association between genetic variants genome-wide and postoperative delirium following major surgery, and to explore whether postoperative delirium shares genetic risk factors with related conditions, specificially delirium of all causes and Alzheimer's disease. The limitations of previous studies are addressed by defining a major surgery cohort in a large scale national biobank and focusing on a single outcome phenotype.

Methods

Study Populations

The data source for the primary analysis was UK Biobank, a long-term prospective cohort study that provides a large-scale biomedical database and research resource containing genetic, lifestyle and health information from half a million UK participants recruited between 2006 and 2010 (http://www.ukbiobank.ac.uk). The UK Biobank study was approved by the North-West Multi-centre Research Ethics Committee and all participants provided written informed consent (16). Additionally, publicly available GWAS summary statistics from the FinnGen study were used as an external cohort for genetic correlation analyses. FinnGen is a large-scale genomics initiative that has analysed over 500,000 Finnish biobank samples and correlated genetic variation with health data to understand disease mechanisms and predispositions. The project is a collaboration between research organisations and biobanks within Finland and international industry partners (17).

Genotyping

UK Biobank genotyping was performed by Affymetrix using two purpose-designed arrays. Genotype data were quality controlled, phased and ~96 million genotypes were imputed using the Haplotype Reference Consortium and UK10K haplotype resources. FinnGen genotyping used a ThermoFisher Axiom custom chip array with imputation to a reference dataset derived from Finnish whole-genome sequences. Further information on the methods and QC pipelines are available (16,18).

Inclusion and exclusion criteria

Eligible participants were those undergoing major, inpatient surgery after their date of enrolment in UK Biobank. Linked hospital inpatient data is available for all UK Biobank participants with follow-up to 31 May 2022 for Wales, 31 August 2022 for Scotland and 31 October 2022 for England (19). Major surgery was defined by OPCS4 code using the Bupa Schedule of Procedures and Abbott classification (20,21) and diagnoses of delirium were identified using International Classification of Diseases, Tenth Revision (ICD-10) code F05. Exclusion criteria included planned day case surgery and a previous diagnosis of delirium (see Supplementary Methods for more detail on phenotype definition and exclusions).

Outcome definition

The primary outcome was a first diagnosis of delirium within 30 days of surgery. Controls were defined as those undergoing major surgery with no delirium diagnosis within 30 days.

Genome-wide Association Study (GWAS)

Case–control GWAS adjusted for sex, genetic chip and the first ten principal components was performed using regenie (v3.2.2) (22). Quality control and ancestry definition were performed by previously established MRC-IEU workflows and methods (23). Post-hoc analyses were conducted using Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA GWAS (24)). Independent significant SNPs were defined as those meeting a genome-wide significance threshold of $p < 5 \times 10^{-8}$ and independent of each other at $r^2 < 0.6$. Lead SNPs were

identified from independent significant SNPs at $r^2 < 0.1$. Gene-based analysis was performed using Multi-marker Analysis of GenoMic Annotation (MAGMA (25)).

The primary GWAS analysis did not include additional clinical covariates as they may be mediators of genetic risk or colliders given the selection of a surgical patient cohort. To explore the robustness of the primary analysis the following sensitivity analyses were performed: a) with adjustment for age; b) after excluding participants who had a previous dementia diagnosis; c) excluding participants who had a previous dementia diagnosis or were diagnosed with dementia after the index procedure; and d) stratified by cardiothoracic/non-cardiothoracic surgery.

Post-GWAS follow-up analyses

Exploratory follow-up analyses were informed by the results of the primary GWAS analysis. Two approaches were taken to formally assess shared genetic architecture between postoperative delirium and a) delirium of any type; b) Alzheimer's Disease: genetic correlation analysis and polygenic risk scoring.

Genetic correlation analysis

Genetic correlation analyses were performed between the UKB GWAS results presented here and the external FinnGen study cohort. GWAS summary statistics (Freeze 9, https://r9.finngen.fi/) were obtained for a) delirium (any cause); and b) Alzheimer's disease. Local Analysis of [co]Variant Association (LAVA (26)) was used to analyse bivariate local genetic correlation between these phenotypes and

postoperative delirium (using the summary statistics from the primary GWAS analysis in UK Biobank).

Polygenic risk score analysis

Polygenic risk scores calculate a weighted sum of risk based on alleles associated with a disease or outcome phenotype. The Polygenic Score Catalog (https://www.pgscatalog.org/) was used to identify polygenic risk scores for Alzheimer's disease. No polygenic risk scores were identified for delirium. The *pgsc_calc* workflow (27) was used to download, variant match and calculate individual polygenic scores for the primary UK Biobank cohort. Individual scores were then centred and scaled before being summed and averaged. Odds ratios for the association between increasing quintile of polygenic risk score for Alzheimer's disease and postoperative delirium were estimated by logistic regression with adjustment for age and sex using the *glm* function in R (version 4.4.0).

Apolipoprotein E (APOE) genotype analysis

It has been recommended that the *APOE* region of chromosome 19 should be excluded from Alzheimer's disease polygenic risk scores, with the *APOE* ε4 allele included as an additional covariate in modelling, due to its outsize effect relative to other regions across the genome (28). The subset of polygenic scores identified above which did not include the *APOE* region (defined as a 10 kilobase window either side of region from the start position of *TOMM40*, 45,394,477, to the stop position of *APOC1*, 45,422,606, build 37/hg19 (28)) were therefore considered in an additional analysis, adjusted for age, sex and *APOE* ε4 allele count (0, 1, 2).

183

Results

Participant characteristics

A total of 1016 cases of postoperative delirium and 139,148 controls were identified (Figure 1). Individuals who developed postoperative delirium tended to be older, male and had higher prevalence of comorbidities (Table 1). Compared to controls, a higher proportion of patients in the postoperative delirium group underwent emergency (532 (52%) vs 29,530 patients (21%)) and cardiothoracic surgery (172 (17%) vs 5041 patients (3.6%)).

Table 1 Participant characteristics for postoperative delirium cases and controls.

	Cases n = 1016	**Controls n = 139,148**	**p-value**
Age (yr), mean (SD)	72 (6)	64 (8)	<0.001
Sex, number (%)			<0.001
Female	384 (38)	77,244 (56)	
Male	632 (62)	61,904 (44)	
Ethnicity, number (%)			0.2
Asian or Asian British	9 (0.9)	2301 (1.7)	
Black or Black British	10 (1.0)	1644 (1.2)	
Chinese	0 (0)	239 (0.2)	
Mixed	5 (0.5)	675 (0.5)	
Other ethnic group	3 (0.3)	984 (0.7)	
White	978 (97)	132,676 (96)	
Missing	11 (1.1)	629 (0.5)	
Charlson Comorbidity Index, median (IQR)	1 (0–3)	0 (0–1)	<0.001
Missing	25 (2.5)	15,817 (11)	
Admission method, number (%)			<0.001
Elective	434 (43)	106,725 (77)	
Emergency	532 (52)	29,530 (21)	
Maternity	0 (0)	113 (<0.1)	
Not known	0 (0)	29 (<0.1)	

Transfer	50 (4.9)	2751 (2.0)	
Surgical specialty, number (%)			<0.001
Cardiothoracic surgery	172 (17)	5041 (3.6)	
General surgery	196 (19)	26,436 (19)	
Neurosurgery	55 (5.4)	5192 (3.7)	
Other	186 (18)	36,532 (26)	
Trauma and orthopaedics	338 (33)	53,722 (39)	
Urology	37 (3.6)	10,628 (7.6)	
Vascular	32 (3.1)	1597 (1.1)	

Numbers are number (proportion), mean (SD) or median (IQR). Additional details can be found in Supplementary table 1.

Genome-wide significant associations for postoperative delirium

Six independent, statistically significant SNPs were identified within a single genetic risk region on chromosome 19 (Figure 2 and 3, Table 2). The lead SNP was rs429358, a missense variant in the *APOE* gene that, together with rs7412, defines the ε2/ε3/ε4 isoforms linked to Alzheimer's disease risk. A total of 26 genes were mapped to this region, including four (*APOE*, *TOMM40*, *APOC1* and *PVRL2***)** that were significantly associated in MAGMA gene-level analysis (Supplementary table 2, Supplementary Figures 1 and 2). Adding age as an additional covariate in the GWAS identified one further independent significant SNP, rs12691088, an intronic variant of the *APOC1* gene (Supplementary table 3).

Table 2 Independent significant single-nucleotide polymorphisms passing genome-wide significance in case-control GWAS of postoperative delirium.

rsID*	Chr:position	Nearest gene	Function	Effect allele	OR (95% CI)	p

rsID*	Chr:position	Nearest gene	Function	Effect allele	OR (95% CI)	p
rs429358	19:45411941	*APOE*	exonic	T	0.56 (0.51-0.62)	1.40×10^{-26}
rs157592	19:45424514	*APOC1*	intergenic	A	0.6 (0.55-0.66)	2.03×10^{-21}
rs157582	19:45396219	*TOMM40*	intronic	C	0.66 (0.6-0.73)	1.13×10^{-15}
rs11556505	19:45396144	*TOMM40*	exonic	C	0.64 (0.58-0.71)	1.71×10^{-14}
rs10119	19:45406673	*TOMM40*	UTR3	G	0.72 (0.66-0.79)	6.46×10^{-12}
rs75627662	19:45413576	*APOE*	downstream	C	0.74 (0.67-0.82)	2.11×10^{-8}

*rsID: Reference SNP cluster ID

GWAS results after excluding existing or incident dementia

After excluding individuals with a pre-existing diagnosis of dementia (56 cases (5.7%) and 375 controls (0.3%)), 5 of the 6 independent significant SNPs remained significant. However, rs75627662 (a downstream variant of *APOE*) no longer reached genome-wide significance. Three genes, *APOE*, *APOC1* and *TOMM40*, remained significant on MAGMA testing (Supplementary figure 3 and 4). When patients who went on to be diagnosed with dementia during UK Biobank follow-up were also excluded (141 cases, 13.9%, and 2358 controls, 1.7%), two SNPs remained genome-wide significant, rs429358 and rs157592. The MAGMA results were unchanged (Supplementary figure 5 and 6).

GWAS results in cardiothoracic and non-cardiothoracic surgery groups

The results for the non-cardiothoracic surgery subgroup (798 cases, 126,973 controls) were similar to those in the overall cohort with five independent significant SNPs identified in the same risk locus on chromosome 19 and three of the four

genes remained significant on MAGMA testing (*APOE*, *APOC1* and *TOMM40*). The lead SNP was the same as in the primary GWAS and the other variants either overlapped with the primary analysis or were in strong linkage disequilibrium (r^2 > 0.97) with them (Supplementary table 4). The cardiothoracic analysis was likely underpowered and returned no genome-wide significant results at $p < 5 \times 10^{-8}$. Multiple SNPs reached a lower indicative threshold of significance including the lead SNP from the primary analysis, rs429358 ($p = 3.8 \times 10^{-7}$; Supplementary table 5).

Genetic correlation with Alzheimer's disease

Significant local genetic correlation was identified on chromosome 19 between postoperative delirium and both delirium of all causes and Alzheimer's disease (Table 3). The correlated region (chr19:45040933-45893307) encompassed the independent significant SNPs from the primary GWAS.

Table 1 Results of Local Analysis of [co]Variant Association (LAVA) testing between postoperative delirium GWAS results and FinnGen GWAS summary statistics.

FinnGen phenotype	**Rho**	**R^2**	**p**
Delirium (all)	0.63 (0.46-0.81)	0.40 (0.22-0.66)	3.7×10^{-10}
Alzheimer's disease	0.68 (0.57-0.80)	0.47 (0.32-0.65)	5.2×10^{-21}

Rho represents the local genetic correlation coefficient. R^2 represents the proportion of variance in postoperative delirium explained by the comparator phenotype.

Association of genetic predisposition for Alzheimer's disease with postoperative delirium

Prior to averaging, forty-two PGS for Alzheimer's disease were identified and passed variant matching (Supplementary table 6). Increased polygenic risk for Alzheimer's disease was associated with increased risk of postoperative delirium in the UK Biobank cohort after adjusting for age and sex (adjusted OR [95% CI] PGS quintile 4: 1.49 [1.2-1.85], PGS quintile 5: 2.29 [1.87-2.8], p <0.001; Table 4).

Table 2 Odds ratio for postoperative delirium by Alzheimer's disease polygenic risk score (PGS) quintile. Results are shown for all 42 polygenic risk scores, adjusted for age and sex, and the subset which did not include the *APOE* region (15 *APOE*-independent scores), adjusted for age, sex and *APOE* ε4 genotype.

Term	**All scores (n=42)**		***APOE*-independent scores (n=15)**	
	Odds ratio (95% CI)	**P value**	**Odds ratio (95% CI)**	**P value**
PGS quintile 1	1.00 (reference)	-	1.00 (reference)	-
PGS quintile 2	1.07 (0.85-1.35)	0.54	1.24 (1.00 – 1.53)	0.052
PGS quintile 3	1.25 (1-1.57)	0.047	1.32 (1.07 – 1.62)	0.01
PGS quintile 4	1.49 (1.2-1.85)	<0.001	1.24 (1.00 – 1.53)	0.049
PGS quintile 5	2.29 (1.87-2.8)	<0.001	1.50 (1.22 – 1.84)	<0.001
Age	1.22 (1.2-1.23)	<0.001	1.22 (1.20 – 1.23)	<0.001
Sex - male	1.82 (1.6-2.07)	<0.001	1.82 (1.60 – 2.07)	<0.001
APOE ε4 x1	-	-	1.75 (1.53 – 2.00)	<0.001
APOE ε4 x2	-	-	4.19 (3.25 – 5.41)	<0.001

Effect of Apolipoprotein E (APOE) genotype on the association of Alzheimer's disease risk with postoperative delirium

Fifteen of the polygenic risk scores identified for Alzheimer's disease contained no variants in the *APOE* region (*APOE*-independent scores, Supplementary table 6).

The effect size of increasing PGS quintile was reduced compared to *APOE*-inclusive scores and the presence of one or more *APOE* ε4 isoforms was associated with increased risk of postoperative delirium (Table 4).

Discussion

In this study, using a large national biobank with linked healthcare data, we identified a genetic risk locus for postoperative delirium on chromosome 19 which included six independent significant SNPs and four mapped genes meeting genome-wide significance. Follow-up analyses in an independent cohort confirmed the presence of shared genetic risk between postoperative delirium and Alzheimer's disease.

Previous GWAS which have included postoperative delirium as an outcome have failed to find any genome-wide significant results, but were likely underpowered (13–15). Our study, to the best of our knowledge the largest GWAS of postoperative delirium to date, is substantially better powered than previous analyses and implicates APOE – an established genetic determinant of Alzheimer's disease – in postoperative delirium risk. The lead SNP identified (*rs429358*) remained significant when patients with a pre-existing or subsequent diagnosis of dementia were excluded, as did the significance of the *APOE* gene on MAGMA testing. We have identified additional genes associated with postoperative delirium (*APOC1*, *TOMM40* and *PVRL2*), which were previously reported to be associated with a range of neurocognitive phenotypes including dementia, cognitive function and decline, brain biomarkers and cerebral imaging metrics (Supplementary table 2, Supplementary figure 7). We did not replicate the results of an earlier candidate gene study that identified an association between the cholinergic genes *CHRM2* and *CHRM4* and postoperative delirium (14) (all three identified variants showed null effects, see Supplementary table 7). However, we used a genome-wide approach which has methodological advantages including increased genetic coverage, reduced bias and lower false positive rates and therefore represents a more robust analysis (29).

Post-GWAS follow-up analyses showed that genetic predisposition for Alzheimer's disease is associated with risk of perioperative delirium, including a dose-response effect of *APOE* ε4 allele count. Previous studies investigating the association between *APOE* ε4 and postoperative delirium have shown mixed results. A recent study of 19,331 patients (2086 of whom had postoperative delirium) found *APOE* ε4 carriers to be at increased risk of neurocognitive disorders compared with non-carriers (30). However, the neurocognitive traits in this study were defined using Phecodes – which include a wider range of medical diagnoses than the more specific ones used in our study (31) – and the authors did not report the timepoint at which outcomes were assessed. Several other studies have found no association (32–34) whilst one small study (29 cases of postoperative delirium) did report increased risk with the ε4 allele (35).

Taken together, these data suggest shared genetic architecture and risk for delirium, whether postoperative or otherwise, and Alzheimer's disease, with multiple clinical implications. Firstly, variants associated with postoperative delirium could be used to risk-stratify patients ahead of surgery to permit alterations to the care pathway such as perioperative care bundles (36). The use of existing polygenic risk scores for related conditions (e.g. Alzheimer's disease) could add additional predictive benefit. Secondly, the acute occurrence of postoperative delirium might be a marker of underlying neurocognitive vulnerability or an undiagnosed chronic condition. If the prediction of increased postoperative delirium risk is also a risk indicator for future Alzheimer's disease then these patients may benefit from additional monitoring long-term. Finally, our findings of shared biological pathways with Alzheimer's disease

could aid in the development of preventive measures for postoperative delirium. For example, acetylcholinesterase inhibitors are widely used in the treatment of Alzheimer's disease but definitive evidence of benefit for the prevention of postoperative delirium is lacking (37,38). Identifying the patient group who might benefit from acetylcholinesterase inhibitors could be one important outcome of genetic studies.

The strengths of this study include the use of a large prospective cohort with linked healthcare data that is subject to rigorous quality control and validation procedures. We defined our exposure using published criteria and employed robust statistical methods to deal with the large case-control imbalance. We were also able to extend our findings through a range of post-GWAS analyses using an independent validation cohort. The study does have some limitations. Whilst UK Biobank represents a large cohort of patients there is a recognised "healthy volunteer" selection bias (39) and so the results may not be entirely generalisable to the wider UK population. Any secondary data analysis relying on routinely-collected administrative data is limited by the fields available, with some potentially relevant factors such as ASA physical status grade and type of anaesthesia not recorded. Similarly, the diagnosis of delirium relied upon ICD-10 clinical coding and was not prospectively screened for. Hospital coding for delirium is consistently found to have low sensitivity but excellent specificity (40). As such we will likely have missed some cases but any resulting bias would have reduced the observed effect, thereby strengthening the validity of our findings. Whilst is also possible that some cases of delirium preceded surgery, the risk of this was minimised as far as possible. Finally, whilst rates of some comorbidities and surgical characteristics differed between

cases and controls, these variables may lie on the causal pathway or act as selection-related colliders in a major surgical cohort. We therefore did not adjust for them in the primary GWAS but examined their influence through a range of sensitivity analyses which support the robustness of our findings.

In conclusion, we have used a large national biobank with linked healthcare data to identify six SNPs and four genes associated with increased risk of postoperative delirium. Data from an independent cohort suggests there is shared genetic architecture and risk between postoperative delirium, delirium more broadly, and Alzheimer's disease. These findings have potential clinical benefit through risk stratification based on genotype or polygenic risk score data, early identification of future Alzheimer's disease risk in the perioperative setting, and the identification of biological targets for the prevention of postoperative delirium.

Authors' contributions

RAA: study design, data analysis, preparing first and subsequent drafts of the paper; PY: study design, drafting paper; BG: study design, drafting paper; GK: study design, drafting paper; TG: study design, drafting paper.

Acknowledgements

This research has been conducted using the UK Biobank Resource under Application Number 128619. This includes linked data provided by patients and collected by the NHS as part of their care and support and data assets made available by National Safe Haven as part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20058).

Quality Control filtering of the UK Biobank data used the process described by R.Mitchell, G.Hemani, T.Dudding, L.Corbin, S.Harrison, L.Paternoster(23).

This work was carried out using the computational and data storage facilities of the Advanced Computing Research Centre, University of Bristol (http://www.bristol.ac.uk/acrc/).

Declaration of interests

TRG receives funding from GlaxoSmithKline, Biogen and Roche for unrelated research. The other authors declare that they have no conflict of interest.

Funding

RAA is funded by a Wellcome Trust GW4-CAT PhD Programme for Health Professionals PhD Fellowship [316275/Z/24/Z]. RAA, PY, GMK and TRG are supported by the Medical Research Council Integrative Epidemiology Unit at the University of Bristol (RA, TG: MC_UU_00032/3; PY: MC_UU_00032/4; GMK: MC_UU_0032/6). GMK acknowledges additional funding from the Wellcome Trust (grant numbers: 201486/Z/16/Z and 201486/B/16/Z), the Medical Research Council (grant numbers: MR/W014416/1; MR/S037675/1; MR/Z50354X/1; and MR/Z503745/1. PY, TRG, and GMK are also supported by the UK National Institute for Health and Care Research (NIHR) Bristol Biomedical Research Centre (grant number: NIHR 203315). The views expressed are those of the authors and not necessarily those of the UK NIHR or the Department of Health and Social Care.

References

1. Evered L, Atkins K, Silbert B, Scott DA. Acute peri-operative neurocognitive disorders: a narrative review. Anaesthesia. 2022;77(S1):34–42.

2. Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. The Lancet. 2014 Mar 8;383(9920):911–22.

3. Gou RY, Hshieh TT, Marcantonio ER, Cooper Z, Jones RN, Travison TG, et al. One-Year Medicare Costs Associated With Delirium in Older Patients Undergoing Major Elective Surgery. JAMA Surg. 2021 May;156(5):462–70.

4. MacLullich AMJ, Ferguson KJ, Miller T, de Rooij SEJA, Cunningham C. Unravelling the pathophysiology of delirium: A focus on the role of aberrant stress responses. J Psychosom Res. 2008 Sep 1;65(3):229–38.

5. Cerejeira J, Firmino H, Vaz-Serra A, Mukaetova-Ladinska EB. The neuroinflammatory hypothesis of delirium. Acta Neuropathol (Berl). 2010 Jun 1;119(6):737–54.

6. Rump K, Adamzik M. Epigenetic Mechanisms of Postoperative Cognitive Impairment Induced by Anesthesia and Neuroinflammation. Cells. 2022 Sep 21;11(19):2954.

7. Swarbrick CJ, Partridge JSL. Evidence-based strategies to reduce the incidence of postoperative delirium: a narrative review. Anaesthesia. 2022;77(S1):92–101.

8. Schenning KJ, Deiner SG. Postoperative Delirium in the Geriatric Patient. Anesthesiol Clin. 2015 Sep 1;33(3):505–16.

9. Nadelson MR, Sanders RD, Avidan MS. Perioperative cognitive trajectory in adults. Br J Anaesth. 2014 Mar 1;112(3):440–51.

10. Goldberg TE, Chen C, Wang Y, Jung E, Swanson A, Ing C, et al. Association of Delirium With Long-term Cognitive Decline: A Meta-analysis. JAMA Neurol. 2020 Nov 1;77(11):1373–81.

11. Peden CJ, Miller TR, Deiner SG, Eckenhoff RG, Fleisher LA, Fleisher L, et al. Improving perioperative brain health: an expert consensus review of key actions for the perioperative care team. Br J Anaesth. 2021 Feb 1;126(2):423–32.

12. Abdellaoui A, Yengo L, Verweij KJH, Visscher PM. 15 years of GWAS discovery: Realizing the promise. Am J Hum Genet. 2023 Feb 2;110(2):179–94.

13. Rickenbacher M, Reinbold CS, Herms S, Hoffmann P, Cichon S, Wueest AS, et al. Genome-wide Association Study of Postoperative Cognitive Dysfunction in Older Surgical Patients. J Neurosurg Anesthesiol. 2022 Apr;34(2):248.

14. Heinrich M, Sieg M, Kruppa J, Nürnberg P, Schreier PH, Heilmann-Heimbach S, et al. Association between genetic variants of the cholinergic system and

postoperative delirium and cognitive dysfunction in elderly patients. BMC Med Genomics. 2021 Oct 21;14(1):248.

15. Westphal S, Stoppe C, Gruenewald M, Bein B, Renner J, Cremer J, et al. Genome-wide association study of myocardial infarction, atrial fibrillation, acute stroke, acute kidney injury and delirium after cardiac surgery - a sub-analysis of the RIPHeart-Study. BMC Cardiovasc Disord. 2019 Jan 24;19(1):26.

16. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018 Oct;562(7726):203–9.

17. Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023 Jan;613(7944):508–18.

18. Genetic data | FinnGen [Internet]. [cited 2025 Sep 1]. Available from: https://www.finngen.fi/en/genetic_data

19.: External Info□: Data_providers_and_dates [Internet]. [cited 2024 Oct 9]. Available from: https://biobank.ndph.ox.ac.uk/showcase/exinfo.cgi?src=Data_providers_and_dates

20. Abbott TEF, Fowler AJ, Dobbs TD, Harrison EM, Gillies MA, Pearse RM. Frequency of surgical treatment and related hospital procedures in the UK: a national ecological study using hospital episode statistics. BJA Br J Anaesth. 2017 Aug 1;119(2):249–57.

21. Bupa - Code Search main [Internet]. [cited 2021 May 12]. Available from: https://codes.bupa.co.uk/procedures

22. Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, et al. Computationally efficient whole-genome regression for quantitative and binary traits. Nat Genet. 2021 Jul;53(7):1097–103.

23. Ruth Mitchell GH. data.bris. 2019 [cited 2024 Oct 9]. UK Biobank Genetic Data: MRC-IEU Quality Control, version 2. Available from: https://data.bris.ac.uk/data/dataset/1ovaau5sxunp2cv8rcy88688v

24. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun. 2017 Nov 28;8(1):1826.

25. Leeuw CA de, Mooij JM, Heskes T, Posthuma D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. PLOS Comput Biol. 2015 Apr 17;11(4):e1004219.

26. Werme J, van der Sluis S, Posthuma D, de Leeuw CA. An integrated framework for local genetic correlation analysis. Nat Genet. 2022 Mar;54(3):274–82.

27. Lambert SA, Wingfield B, Gibson JT, Gil L, Ramachandran S, Yvon F, et al. Enhancing the Polygenic Score Catalog with tools for score calculation and ancestry normalization. Nat Genet. 2024 Sep 26;1–6.

28. Ware EB, Faul JD, Mitchell CM, Bakulski KM. Considering the APOE locus in Alzheimer's disease polygenic scores in the Health and Retirement Study: a longitudinal panel study. BMC Med Genomics. 2020 Nov 3;13:164.

29. Menon DK, Rosand J. Finding a Place for Candidate Gene Studies in a Genome-Wide Association Study World. JAMA Netw Open. 2021 Jul 26;4(7):e2118594.

30. Thedim M, Hu J, Maher M, Wiener-Kronish J, Saxena R, Vacas S. Perioperative polygenic and APOE-based genetic risk assessment for neurocognitive disorders: a biobank study. Br J Anaesth [Internet]. 2025 Jun 24 [cited 2025 Jul 4];0(0). Available from: https://www.bjanaesthesia.org/article/S0007-0912(25)00308-3/fulltext

31. Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol. 2013 Dec;31(12):1102–11.

32. Abelha FJ, Fernandes V, Botelho M, Santos P, Santos A, Machado JC, et al. Apolipoprotein E e4 allele does not increase the risk of early postoperative delirium after major surgery. J Anesth. 2012 Jun 1;26(3):412–21.

33. Vasunilashorn S, Ngo L, Kosar CM, Fong TG, Jones RN, Inouye SK, et al. Does Apolipoprotein E Genotype Increase Risk of Postoperative Delirium? Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry. 2015 May 21;23(10):1029.

34. Tagarakis GI, Tsolaki-Tagaraki F, Tsolaki M, Diegeler A, Tsilimingas NB, Papassotiropoulos A. The Role of Apolipoprotein E in Cognitive Decline and Delirium after Bypass Heart Operations. Am J Alzheimers Dis Dementias®. 2007 Jun 1;22(3):223–8.

35. Leung JM, Sands LP, Wang Y, Poon A, Kwok P yan, Kane JP, et al. Apolipoprotein E e4 Allele Increases the Risk of Early Postoperative Delirium in Older Patients Undergoing Noncardiac Surgery. Anesthesiology. 2007 Sep 1;107(3):406–11.

36. Meco BC, Jakobsen K, De Robertis E, Buhre W, Alkış N, Kirkegaard PR, et al. A first assessment of the safe brain initiative care bundle for addressing postoperative delirium in the postanesthesia care unit. J Clin Anesth. 2024 Oct 1;97:111506.

37. Gamberini M, Bolliger D, Lurati Buse GA, Burkhart CS, Grapow M, Gagneux A, et al. Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery—A randomized controlled trial*. Crit Care Med. 2009 May;37(5):1762.

38. Youn YC, Shin HW, Choi BS, Kim S, Lee JY, Ha YC. Rivastigmine patch reduces the incidence of postoperative delirium in older patients with cognitive impairment. Int J Geriatr Psychiatry. 2017;32(10):1079–84.

39. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. Am J Epidemiol. 2017 Nov 1;186(9):1026–34.

40. Chuen VL, Chan ACH, Ma J, Alibhai SMH, Chau V. Assessing the Accuracy of International Classification of Diseases (ICD) Coding for Delirium. J Appl Gerontol. 2022 May;41(5):1485–90.

Figure legends

Figure 1 Study flow diagram.

Figure 2 Manhattan plot of GWAS results. The red line represents a genome-wide significant p value of 5×10^{-8}.

Figure 3 Q-Q plot of GWAS results. Genomic inflation factor (λ) 1.017.


UK Biobank participants
n=488,377
No qualifying surgery
n=347,814
Major inpatient surgery
n=140,563
Previous or co-existent delirium
n=399
Delirium within 30 days
n=1016
No delirium within 30 days
n=139,148


-log10 P-value
0
2
4
6
8
10
12
14
16
18
20
22
24
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
Chromosome


Observed -log10 P-value
Expected -log10 P-value
0
2
4
6
8
10
12
14
16
18
20
22
24
26
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
5.5
6.0
6.5